Given this accumulating evidences, the American Diabetes Association (ADA) and the Chinese Diabetes Society recommend the cardio-protective glucose-lowering drug classes (GLP-1 RA and SGLT2i), ACEI/ARB, statins, and aspirin for comprehensive cardiovascular risk reduction in adults patients with T2DM and established or high risk of ASCVD (16, 17). This evidence concerns the gene GLP1R and diabetes mellitus.